References
Patents
- Fischer G, Bar-Shalom D, Slot L, Lademann A-M: US20070042044 (2007).
- Costantini D, Lemarchand C: US8211466 (2012).
Websites
- GSK to acquire Human Genome Sciences for US$14.25 per share in cash. www.gsk.com/media/pressreleases/2012/2012-pressrelease-1183501.htm (Accessed 11September2012)
- GSK confirms offer to acquire Human Genome Sciences for US$13.00 per share in cash. www.gsk.com/media/pressreleases/2012/2012-pressrelease-1046736.htm (Accessed 15August2012)
- Human Genome Sciences website. www.hgsi.com (Accessed 11September2012)
- GSK completes acquisition of Human Genome Sciences. www.gsk.com/media/pressreleases/2012/2012-pressrelease-1206563.htm (Accessed 11September2012)
- pSivida Corp. announces tech evaluation agreement for Tethadur™ protein/antibody delivery system with leading biopharmaceutical company. http://psdv.client.shareholder.com/releasedetail.cfm?ReleaseID=696396 (Accessed 12September2012)
- Regulus Therapeutics forms strategic alliance for discovery, development and commercialization of microRNA therapeutics with AstraZeneca. www.regulusrx.com/regulus-therapeutics-forms-strategic-alliance-for-discovery-development-and-commercialization-of-microrna-therapeutics-with-astrazeneca (Accessed 11September2012)
- Arrowhead enters into antibody candidate evaluation agreement with Merck. www.arrowheadresearch.com/press-releases/arrowhead-enters-antibody-candidate-evaluation-agreement-merck (Accessed 12September2012)
- Arrowhead Research Corporation acquires Alvos Therapeutics and Proprietary Library of targeting peptides. www.arrowheadresearch.com/press-releases/arrowhead-research-corporation-acquires-alvos-therapeutics-and-proprietary-library (Accessed 12September2012)
- Chiasma closes $38.5 million equity financing. www.chiasmapharma.com/TickerPage.asp?id=8 (Accessed 12September2012)
- Entry for Sandostatin LAR® depot on Drugs@FDA. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo (Accessed 12September2012)
- Chiasma website. www.chiasmapharma.com/Page.asp?id=1 (Accessed 12September2012)
- Halozyme confirms Baxter has received a complete response letter for HyQ BLA. www.halozyme.com/Investors/News-Releases/News-Release-Details/2012/Halozyme-Confirms-Baxter-Has-Received-A-Complete-Response-Letter-For-HyQ-BLA1130436/default.aspx (Accessed 13August2012)
- Halozyme Therapeutics website. www.halozyme.com (Accessed 15September2012)
- FDA approves Lucentis® (ranibizumab injection) for Treatment of diabetic macular edema (DME). www.gene.com/gene/news/pressreleases/display.do?method=detail&id=14127 (Accessed 13September2012)
- US FDA entry on Lucentis on Drugs. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo (Accessed 13September2012)
- Roche‘s Lucentis works to treat vision loss from diabetes – article by Anna Edney on Bloomberg website. www.bloomberg.com/news/2012-07-24/roche-s-lucentis-works-to-treat-vision-loss-from-diabetes.html (Accessed 13September2012)
- Alnylam reports positive ALN-TTR02 clinical data, with robust knockdown of serum transthyretin (TTR) of up to 94% after single dose. http://phx.corporate-ir.net/phoenix.zhtml?c=148005&p=irol-newsArticle&ID=1714793&highlight= (Accessed 15September2012)
- FDA advisory committee finds data support effectiveness of Tafamidis Meglumine, Pfizer‘s novel investigational treatment for transthyretin familial amyloid polyneuropathy (TTR-FAP). www.pfizer.com/news/press_releases/pfizer_press_release.jsp?guid=20120524006494en&source=RSS_2011&page=5 (Accessed 15September2012)
- Egalet announces issuance of US patent. Press release on PR Newswire. www.prnewswire.com/news-releases/egalet-announces-issuance-of-us-patent-163530176.html (Accessed 16September2012)
- Egalet website. http://egalet.com/index.dsp?area=5 (Accessed 16September2012)
- BioAlliance Pharma announces the grant of US patent covering Sitavig®. www.bioalliancepharma.com/eng (Accessed 16September2012)